- Home
- BCAB vs CLRB Comparison
BCAB vs CLRB Comparison
Compare BCAB & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | CLRB |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 12.9M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | BCAB | CLRB |
|---|---|---|
| Price | $0.18 | $3.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.5M | 44.2K |
| Earning Date | 06-15-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.19 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.23 |
| 52 Week High | $1.43 | $10.19 |
Technical Indicators
Market Signals| Indicator | BCAB | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 55.44 |
| Support Level | $0.14 | $3.19 |
| Resistance Level | $0.27 | $3.60 |
| Average True Range (ATR) | 0.02 | 0.30 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 19.32 | 73.82 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.